Αρχική World News No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive... World News No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Από Ogkologos - 17 Νοεμβρίου, 2025 405 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec 24 Απριλίου, 2026 Coronavirus Vaccines and People with Cancer: A Q&A with Dr. Steven... 10 Φεβρουαρίου, 2021 After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms 11 Απριλίου, 2019 Neoadjuvant Camrelizumab Plus Chemotherapy Demonstrate Superior pCR Compared to Chemotherapy Alone... 29 Ιουλίου, 2024 Φόρτωση περισσοτέρων HOT NEWS Removing senescent immune cells could be the key to preventing some... The director’s cut: How Dr Catherine Elliott sees the future of... Pembrolizumab Demonstrates Robust and Durable Antitumour Activity in Patients with Previously... Radionuclide Therapy Could Be A Viable Treatment For Early-Stage Breast Cancer,...